London; United Kingdom
Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris Cell stems from the collaboration between researchers at two institutions, the biomaterials group at Barcelona’s IQS and the group for the Regulation of the Genetic Expression and Stability of Stem Cells at a leading organisation.
ANDVARI ALVA is a long-term oriented, family-owned investment company based in Berlin. Originally founded in 2001 as an institute affiliated to the Berlin University of the Arts, the company today invests primarily in sustainable business models.
BioMediTech, a joint institute of Tampere University of Technology and University of Tampere, brings together a powerful mix of multidisciplinary expertise in life sciences and medical technology. Over 250 scientists conduct research and education in the fields of cell and molecular biology, genetics, biomaterials, biosensors, computational systems, biotechnology, biomedical engineering, and regenerative medicine.
Biotechnological Armenian Association
Yerevan; Republic of Armenia
The Biotechnological Armenian Association based in Yerevan has been active since 2007 and unites all Armenian organisations in the field of biotechnology/life sciences.
Campania Bioscience Scarl
Campania Bioscience is a regional cluster set in Naples (Campania region – Southern Italy) gathering together competences and facilities in the fields of Health, Biotech and Agro-food, with the aim of valorising partners’ expertise in the value chain, stimulating exploitation of cluster assets, supporting knowledge transfer and encouraging international networking and partnerships.
China Bioengineering Technology Group Ltd
Hong Kong; China
China Bioengineering Technology Group Limited (CBT) is located in Hong Kong Science Park. It is a high-tech professional body comprising of biomedical science, precision medicine, as well as big data access, statistics and analysis. Our company possesses the independent intellectual property right for gene testing technology and platform for biomedical data analysis?including the patent for genetic testing and copyright for genetic testing software.
EphyX Neuroscience is a CRO specialized in in vitro & in vivo electrophysiology applied to drug discovery and CNS-related preclinical studies. Our goal is to efficiently help our clients optimize their compound selection to limit the risk of failure at later stages. Our highly qualified experts perform recordings in acute slices from both rodent and human, which makes our data truly predictive.
Health and Life Sciences Cluster
The potential for value creation in the emerging bioeconomy is huge, both for people and society, and for business and industry. Bulgaria is well positioned to become a significant contributor to this development. Health & Life Science Cluster’s mission is to improve quality in treatment and care by developing and industrializing world class health solutions.
Nijmegen; The Netherlands
For over twenty years Hezelburcht has provided (full service) grant support to assist clients in achieving their strategic, financial and innovative ambitions. Knowledge of grants, including regional and European programmes, as well as experience in both the public and private sectors enables Hezelburcht to offer a full spectrum of services related to grants and incentives. It has become one of the largest service providers in the field of grant consultancy and grant management in the Netherlands.
Kizoo Technology Capital GmbH
KIZOO provides mentoring, seed and early-stage financing with a focus on rejuvenation biotech. As part of the Forever Healthy Group, we directly support the creation of startups that turn research on the root causes of aging into therapies and services for humans. Initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.
OP2 Drugs SAS ("OP2")
OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.
London; United Kingdom
Pharmidex provides translational solutions using its world renowned expertise in CNS/oncology, drug discovery and ADMET/pharmacokinetics. Founded in the UK in 2002, Pharmidex operates in state-of-the-art facilities in London and Stevenage to provide high-quality bespoke experimental data to support drug discovery and development.
Recipharm was established in Sweden in 1995 and has since grown to become a leading Contract Development and Manufacturing Organisation (CDMO). Headquartered in Stockholm, employing nearly 5 000 people and the Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
Liverpool, United Kingdom
Redx Pharma has quickly established itself as one of the largest biotechnology companies in Europe, focused on the development of a wide range of early stage, proprietary small molecule therapeutics to address high unmet medical needs in cancer and infectious disease.
Talk Biotech Ltd
Cheshire; United Kingdom
Talk Bio provides IRB approved and ethically sourced human diseased and normal tissues, biofluids & cells from over 150 global clinical sites, along with technologies including RT-qPCR, NGS, Sanger sequencing, flow cytometry, IHC, ISH and image analysis to support your in-house teams with biomarker assay development, validation & screening services.
Tissue Solutions Ltd
Glasgow; United Kingdom
Through Tissue Solutions’ global network you can reliably and efficiently source valuable biological material adhering to the highest possible ethical standards. We are an ISO 9001:2015 certified company and offer a single access point for a wide range of diseased and normal tissues in fresh, frozen, and FFPE formats.
University of Birmingham
Birmingham; United Kingdom
Birmingham is constantly developing and evolving in its desire to become a leading global university. This is being achieved through the enhanced research power and reach; the distinctiveness of exceptional student experience; the breadth and depth of academic portfolio; size and extent of the global networks.